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Docetaxel and sodium selenite are well known for their anticancer properties. While resistance to doce-
taxel remains an obstacle in prostate cancer chemotherapy, sodium selenite, has been exploited as a new
therapeutic approach. Currently, development of therapies affecting a multitude of cell targets, have been
proposed as a strategy to overcome drug resistance. This association may reduce systemic toxicity coun-
teracting a wide range of side effects.
Here we report the effect of docetaxel and sodium selenite combination on the PC3 prostate cancer cell
line, derived from bone metastasis. Therefore we evaluate cell growth, cell cycle progression, viability,
mitochondria membrane potential, cytochrome C, Bax/Bcl2 ratio, caspase-3 expression and reactive oxy-
gen species production.
Our results suggest that sodium selenite and docetaxel combination have a synergistic effect on cell
growth inhibition (67%) compared with docetaxel (22%) and sodium selenite (24%) alone. This combina-
tion also significantly induced cell death, mainly by late apoptosis vs necrosis, which is correlated with
mitochondria membrane potential depletion. On the other hand, cytochrome C, Bax/Bcl2 ratio and cas-
pase-3, known as proapoptotic factors, significantly increased in the presence of sodium selenite alone,
but not in the presence of docetaxel in monotherapy or in combination with sodium selenite.
These findings suggest that docetaxel and sodium selenite combination may be more effective on pros-
tate cancer treatment than docetaxel alone warranting further evaluation of this combination in prostate
cancer therapeutic approach.
 2011 Elsevier Inc. All rights reserved.1. Introduction
Prostate carcinoma is the most commonly diagnosed malig-
nancy and the second leading cause of cancer-related mortality
in men in the Western Countries [1,2].
Besides clinical and scientific efforts on prostate cancer, conven-
tional therapies fail to eliminate advanced tumors. As prostate can-
cer cell growth is androgen dependent, its deprivation is an
important therapeutic strategy. However, long-term androgen-ll rights reserved.
oratory, Faculty of Medicine,
Portugal. Fax: +351 239 822
reitas), valves@fmed.uc.pt (V.
-Ribeiro), apinto@fmed.uc.ptablation results in androgen-independent cancer cell growth in
metastatic patients, leading to hormone refractory prostate cancer
(HRPC) [3].
Chemotherapy, using Taxotere (docetaxel), a member of taxane
family remains the standard option for patients at the advanced
stages, namely in the HRPC [4]. Docetaxel binds to microtubules
and promotes their polymerization, assembly and stabilization,
inhibiting mitosis and cell cycle progression via G2M phase arrest.
It also down regulates the anti-apoptotic Bcl-2 expression [4–9],
enhances the apoptosis induced by ‘‘tumor necrosis factor-related
apoptosis-inducing ligand’’ (TRAIL) [8], down regulates genes in-
volved in cell cycle progression (cyclin A, cyclin F, CDC2, CDK2,
BTG, etc.), transcription factors (transcription factor A, ATF5, TAF
1 31L, etc.), oncogenes (GRO, BRCA1, p120, etc.) and apoptosis as
GADD45A [6–9]. However, cancer cells become resistant and there-
fore docetaxel therapy is limited. Makarovskiy et al. [10] found that
continuity of drug exposure induces the formation of resistant
giant multinucleated clones.
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has generated considerable interest in prostate cancer chemopre-
vention. This protective effect results from a combination of vari-
ous mechanisms as the prevention of DNA damage, oxidative
stress and inflammation. It may also activate enzyme detoxifica-
tion mechanisms by selenoproteins activation as glutathione per-
oxidase (Gl-Ppx) (for review see Nadiminity and Gao [11]).
Nevertheless, recent studies demonstrate that higher selenium
concentrations have anticancer activity by inducing cell growth
inhibition and apoptosis on prostate cancer cells [12–16] concom-
itantly with an increase in Bax/Bcl2 ratio, Bak and Bid proteins and
decrease in Bcl2 expression [16].
Selenium related-apoptosis is induced by oxidative stress,
resulting from antioxidant defenses depletion, namely, reduced
glutathione/oxidized glutathione (GSH/GSSG), along with an in-
crease of superoxide and hydrogen peroxide production in prostate
cancer cells [13,15]. Moreover, sodium selenite (Na2SeO3), an inor-
ganic form of selenium, alters subcellular distribution of manga-
nese superoxide dismutase (MnSOD), another important
antioxidant defense, inducing its depletion in mitochondria and
its increase in cytosol [17].
Menter et al. [12] found that sodium selenite is more potent
than the organic selenomethionine (SeMet) form as an apoptotic
inducer. Furthermore, Jiang et al. [18] demonstrated that the expo-
sure of the androgen independent prostate cancer cells, DU145, to
SeMet vs sodium selenite induced differential patterns on cell cycle
arrest and apoptosis, as well as distinct effects on AKT, ERK1/2,
JNK1/2, and p38MAPK phosphorylation and p27kip1 and p21cip1
expression. Concomitantly, selenite exposure caused S-phase ar-
rest and induced apoptotic DNA fragmentation caspase-indepen-
dent, which were associated with the decrease of p27kip1 and
p21cip1 expression and the increased of AKT, JNK1/2, and
p38MAPK phosphorylation.
Lack of curative treatments at the advanced prostate cancer,
underline the importance of additional trials for the successful
development of an effective therapeutic approach. As it is clear
that sodium selenite and docetaxel affects a multitude of targets
instead of just one key, we are interested to evaluate if docetaxel
and sodium selenite combination results in a synergistic anticancer
effect that could contribute to lower systemic toxicity.2. Materials and methods
2.1. Cell culture conditions
Human prostate cancer cell line, PC3, derived from bone metas-
tasis [19] represents the advanced stages of this disease and was
purchased from the American Type Culture Collection (ATCC).
Cell growth was performed in RPMI 1640 medium (Sigma) with
10% (v/v) heat-inactivated fetal bovine serum (FBS) (Biochrom) and
2 mM L-glutamine (Sigma), supplemented with 100 U/ml Penicil-
lin, 100 lg/ml Streptomycin and with 5 lg/ml Kanamycin (Sigma).
Cells were maintained in a 95% humidified incubator with 5% CO2
at 37 C, and were passaged with trypsinization every fourth day.
For assays, PC3 were seeded in a concentration of 3  105 cells/
ml. After being cultured up to 80% confluence, cells were washed
once with fresh assay medium and treated for 24–72 h with the So-
dium Selenite (Sigma) (10 nM to 5 lM) and/or docetaxel (Taxotere,
Aventis) (5–250 nM) dissolved in 13% (v/v) ethanol.2.2. Growth inhibition assays
Cell proliferation was measured by the colorimetric MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (Sig-
ma) method that quantifies the reduction of the yellow tetrazoliumsalt to purple formazan crystals by the mitochondria of viable cells
[20]. Briefly, after the treatment on 96-well plates, the cells were
washed with 0.2 ml of PBS (Gibco) and each well was replaced
by 0.1 ml of MTT (0.5 mg/ml) in medium salt (132 mM NaCl,
4 mM KCl, 1.2 mM Na2HPO4, 6 mM Glucose and 10 mM Hepes buf-
fer), supplemented with 1 mM CaCl2 (Sigma). Cells were then incu-
bated at 37 C for 2 h. To each well was added 0.1 ml of 0.04 M HCl
in isopropanol to dissolve the formazan crystals. Optical density
values, measured at 570 nm in a microplate reader (BioRad, Model
680) were use to determine the reduction of tetrazolium. IC50 val-
ues were defined as the half maximal inhibitory concentration.
2.3. Flow cytometry studies
Flow cytometry studies were performed according to the fol-
lowing protocol: after 24 h incubation, 1  106 cells and corre-
sponding controls were collected by trypsinization and washed
two times in PBS buffer by centrifugation for further acquisition
and analysis in a FACScalibur (488 and 635 nm), using the Cellquest
and Paint-a-gate software (BD Bioscience). At least 10,000 events
were collected for viability and cell death, Dwm, ROS (peroxides),
cytochrome C, caspase 3 analyses and Bax/Bcl2 ratio determina-
tion, whereas, 20,000 events were collected for cell cycle assays.
2.4. Cell cycle analyses
Cell cycle distribution was assessed by analyses of DNA content
[21,22] using a kit (Cytognos) with adaptations. Briefly, 1  106
cells were collected and treated with 1 ml DNA labeling solution,
containing detergent, propidium iodide and RNAse. Samples were
then incubated in the dark for 10 min, at room temperature in a
horizontal position and immediately analyzed by flow cytometry.
2.5. Cell death studies
2.5.1. Apoptosis and/or necrosis evaluation
Identification of cell death by apoptosis and/or necrosis was
performed after collecting total treated cells. Samples were labeled
with Annexin-V (BD Biosciences) and propidium iodide (PI) (Invit-
rogen-Molecular Probes) according to the manufacture’s instruc-
tions. After washed, 1  105 collected cells were resuspended in
100 lL of binding buffer (0.025 M CaCl2, 1.4 M NaCl, 0.1 M Hepes)
containing 5 lL of annexin-V APC and 2 lL of propidium iodide (PI)
(3 lM) and then kept in the dark at room temperature for 15 min.
Cells were resuspended in a final volume of 500 lL of binding buf-
fer and were analyzed immediately by flow cytometry [23].
2.5.2. Bax/Bcl2 ratio, cytochrome C and caspase 3 assays
Determination of Bax, Bcl2, cytochrome C and caspase 3 were
performed by flow cytometry after labeling the cells with mono-
clonal antibodies combined with fluorescent probes.
Cells were permeabilized and fixed with 250 ll of cytofix–cyto-
perm (Cytofix/cytoperm kit, Pharmigen) for 20 min at 4 C and
washed with perm-wash (Cytofix/cytoperm kit), and centrifuged
at 1500 rpm for 5 min.
Bax and Bcl2 antibodies were purchased from Santa Cruz Bio-
technology and (pharmingen (BD)), respectively. Cells were labeled
with 2 lg Bax and 1 lg Bcl2 combined with phycoerythrin and
fluorescein isothiocyanate (FICT), respectively, incubated for
15 min in the dark and then washed one time.
For caspase detection, cells were labeled with 2 lg caspase anti-
body combined with phycoerythrin (pharmingen (BD)) followed
by 45 min incubation in the dark. Cytochrome C, primary antibody
(0.5 lg) (Santa Cruz) was added to the cells followed by 15 min
incubation in the dark and washed once. Cells were then labeled
with (0.5 lg) secondary antibody combined with phycoerythrin
Fig. 1. Dose–response curves. Effect of docetaxel (A) and sodium selenite (B) alone and in combination (C) on PC3 cells growth was evaluated through the formation of
formazan products, by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), each 24 h, during 72 h of incubation as described in Section 2. Absorbance
values were normalized to the values obtained for the control cells. Controls correspond to untreated and treated cells with 0.13% ethanol for sodium selenite and docetaxel
assays, respectively. Results are expressed as the mean ± SD of at least 3 separate experiments. Significant differences of combined effect relative to controls, namely, 100 nM
docetaxel and 2.5 lM sodium selenite are considered for ⁄⁄⁄p < 0.001 and +++p < 0.001, respectively.
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immediately analyzed by flow cytometry.
2.6. Mitochondrial membrane potential (Dwm) determination
In order to detect Dwm, attached cells, considered as the alive
cells, were collected and then labeled with the fluorescent
probe 5,50,6,60-tethrachloro-1,103,30-tetraethylbenzimidazolylcar-
bocyanine iodide (JC1) (Cell Technology) according tomanufacture’sinstructions. Briefly 5  105 cells were resuspended in 0.5 ml of 1
JC-1 reagent solution and then incubated during 15 min, at 37 C
in a 5% CO2 chamber. Cells were washed two times with 2 ml 1 as-
say buffer, resuspended in 0.5 ml 1 assay buffer andwere analyzed
immediately by flow cytometry.
JC1 is a lipophilic cationic probe, developed by Cossariza et al.
[24], able to cross the intact mitochondria membrane, forming J-
aggregates (A), which are associated with a large shift in emission
(590 nm). However, in lower polarized mitochondrial membrane,
Fig. 2. Evaluation of docetaxel and sodium selenite on cell death, viability andDwm. Cells were treated for 24 h with 2.5 lM sodium selenite and 100 nM docetaxel, alone and
in combination. Cell death and viability results (2A) are relative to alive cells (A), initial apoptotic cells (IA), necrotic cells (N) and late apoptotic/necrotic cells (LA/N). Results
were expressed as the percentage of cells staining with the respective molecular probe and represent the means ± SD of at least triplicate determinations. Significant
differences on apoptosis vs necrosis relative to control, docetaxel and sodium selenite are considered for ⁄⁄⁄p < 0.001; +++p < 0.001 and ###p < 0.001, respectively. Mitochondria
membrane potential (Dwm) results (2B) are expressed as the ratio of Monomers/Aggregates (M/A) that are inversely proportional to Dwm. Results represent the means
Dwm ± SD of at least triplicate determinations. Significant viability differences are considered for each assay: ⁄p < 0.05 vs control and #p < 0.05 vs docetaxel and +p < 0.05 vs
sodium selenite.
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emitting at 527 nm upon excitation at 490 nm. The ratio between
M/A is inversely correlated with the Dwm.2.7. Reactive oxygen species (peroxides) determination
Intracellular levels of peroxides were quantified labeling
5  105 cells with 5 lM 2,7-dichlorofluorescein diacetate (DCFH2-
DA) (Sigma) according to Rothe and Valet [25] adaptations. Briefly,
cells were incubated during 1 h at 37 C, in the dark, washed 2
times in 0.5 ml phosphate-buffered saline (PBS), resuspended in
0.5 ml PBS and immediately analyzed by flow cytometry.
This methodology is based on the conversion of (DCFH2-DA) to
DCFH2 by intracellular esterases that is consequent converted in
the highly fluorescent 2,7-dichlorofluorescein (DCF) by ROS. The
resultant green fluorescence is proportional to the intracellular le-
vel of ROS, upon excitation at 488 nm.2.8. Statistical analyses
All the data are expressed as mean ± SD of the indicated number
of experiments. Significance was assessed for P values <0.05
according to T-tests.Cell proliferation dose–response curves were fitted to 3 param-
eter sigmoid equation through computer-assisted curve fitting
(SigmaPlot 11.0).3. Results
3.1. Antiproliferative effect of docetaxel and sodium selenite on
prostate cancer cells
Docetaxel and sodium selenite inhibit prostate cancer cells
(PC3) growth in a dose and time dependent-manner.
Half maximal inhibitory concentration values (IC50) of doce-
taxel (Fig. 1A) and sodium selenite (Fig. 1B) were reached for
approximately 500 nM (Rsqr: 0.998) and 10 lM (Rsqr: 0.991),
respectively, after 24 h incubation. However, when we treat the
cells with 100 nM docetaxel and 2.5 lM sodium selenite simulta-
neously, we observed a synergistic antiproliferative effect
(Fig. 1C). In fact, sodium selenite and docetaxel combination have
a synergistic effect on cell growth inhibition (67%) compared with
docetaxel (22%) and sodium selenite (24%) alone. Interestingly, sel-
enite and docetaxel induced synthesis (S) and G2M phase arrest
respectively, while, the combination drugs induced G2M and S
phase arrest simultaneously, reflecting a synergistic effect (Table 1).
Fig. 3. Effect of sodium selenite and docetaxel on Bax/Bcl2 ratio, cytochrome C and caspase 3. Following 24 h treatment with 100 nM docetaxel and 2.5 lM sodium selenite,
the effects on Bax/Bcl2 ratio (A), cytochrome C (B) and caspase 3 (C) were evaluated, on PC3 cells, by flow cytometry. The data are expressed as the mean ± SD of at least
duplicate determinations (⁄p < 0.05 vs control).
Fig. 4. Evaluation of ROS levels in PC3 cells treated with sodium selenite combined with docetaxel. Peroxides were assessed by flow cytometry labeling the cells with 5 lM
2,7-dichlorofluorescein diacetate (DCFH-DA) probes as described in materials and methods. The results were expressed as the means intensity fluorescence (MIF) ± SD of at
least triplicate determinations. Significant differences of ROS production relative to control, docetaxel and sodium selenite are considered for ⁄⁄⁄p < 0.001 and ⁄⁄p < 0.01;
###p < 0.001 and ++p < 0.05, respectively.
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Table 1
Effect of sodium selenite and docetaxel combination in PC3 cell cycle.
Cell cycles (%) G0/G1 G2M S
Control 64.9 14.6 20.5
100 nM docetaxela 17.2 63.5 19.3
2.5 lM sodium selenitea 29.3 26.1 44.6
100 nM docetaxel + 2.5 lM sodium selenitea 23.1 33.9 43
a Significant alterations compared to control.
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In order to examine if the anti-proliferative effect was accom-
plished by cell cytotoxicity, we analyzed cell viability and death
by flow cytometry labeling the cells with Annexin-V/Propidium Io-
dide. Alive cells (A) exclude propidium iodide and do not bind an-
nexin-V. Apoptotic cells with intact membranes exclude
propidium iodide, externalize phosphatidylserine to the outside
of the plasma membrane and therefore bind Annexin V (IA) caus-
ing the apoptotic cell to emit fluorescence. Propidium iodide stains
nuclear DNA of necrotic (N) and late apoptosis/necrosis cells (LA/
N).
Here we found that docetaxel and sodium selenite combination
is more effective to induce cell cytotoxicity than either alone, play-
ing an additive effect, and that cell death is mainly by apoptosis
and apoptosis vs necrosis (Fig. 2A). The results agree with Dwm
depletion (Fig. 2B).
3.3. Sodium selenite increases the expression of apoptotic signals
Bcl2 and Bax are members of the Bcl2 family involved in apop-
tosis regulation, playing an antiapoptotic and proapoptotic role,
respectively [26]. To analyze some of the mechanisms, which
may participate in cell death induced by sodium selenite alone
and in combination with docetaxel, we evaluate Bax/Bcl2 ratio,
cytochrome C and caspase 3 expression. Fig. 3 indicates an increase
in the apoptotic molecules, namely, cytochrome C and caspase 3 as
well in the Bax/Bcl2 ratio, comparing to control.
3.4. Sodium selenite and docetaxel induced-cytotoxicity is associated
with peroxides depletion
Next we test the hypothesis weather sodium selenite and doce-
taxel combination-induced cytotoxicity could be associated to ROS
production. As shown in Fig. 4, sodium selenite alone and com-
bined with docetaxel induced ROS depletion in PC3 cells, after
24 h treatment.4. Discussion
Prostate cancer may develop from an androgen dependent stage
responding to androgen ablation therapy and progresses to a fur-
ther hormone refractory prostate cancer (HRPC) that is resistant
to radiotherapy and chemotherapy, namely Taxotere (docetaxel)
[4]. At this stage prostate cancer cells may have loose androgen
receptor as occurs in PC3 cell line, derived from bone metastasis
and therefore representing the advanced stages prostate cancer
[10].
Lack of curative treatments underline the importance of addi-
tional trials for the development of a successful and effective ther-
apeutic approach in prostate cancer. Sodium selenite has been
recognized by its anticancer properties and its chemoprotective ac-
tion [11].
Therefore we are interested to evaluate if sodium selenite and
docetaxel combination results in a synergistic anticancer effect
on prostate cancer cells that could also contribute to systemic tox-
icity reduction. Data not shown indicate that docetaxel has a high-
er antiproliferative effect on PC3 cells, compared to HPV10, from
localized prostate adenocarcinoma and RWPE1, from normal pros-
tate epithelium. Moreover, we confirm that docetaxel alone did not
induce cell death [9,11]. Makarovskiy et al. [10] demonstrate that
androgen independent cells, including PC3, develop resistance to
docetaxel due to continuity of drug exposure.
On the other hand, we confirm that sodium selenite induced cell
death in PC3, as previously documented, in other prostate cancercells as DU145, LNCaP and LAPC-4 [12,13]. Moreover, our major
findings indicate that sodium selenite and docetaxel, in combina-
tion, play a synergistic antiproliferative effect on prostate cancer
(Fig. 1C) and an additive cytotoxic effect, mainly by apoptosis vs
necrosis (Fig. 2A), in line with Dwm depletion (Fig. 2B).
Docetaxel and selenite inhibits cell growth (Fig. 1A and B),
arresting cells to G2M and S phase, respectively, in prostate cancer
cells (Table 1) [12,18,21].
We subsequent evaluated some molecules that could be in-
volved in cell death signaling. Therefore we analyzed the expres-
sion of Bcl2 and Bax, playing an antiapoptotic and proapoptotic
role, respectively. Bax targets the mitochondria to antagonize
Bcl2 effect and promotes the release of cytochrome C that activates
caspase 3 [26]. Sodium selenite, but not docetaxel, induces an in-
crease in Bax/Bcl2 ratio, cytochrome C and caspase 3 expression
(Fig. 3) as demonstrated by others [8,13,15]. However, the aug-
mented apoptotic vs necrotic effect, resulting from drugs combina-
tion was not associated to an increase of Bax/Bcl2 ratio cytochrome
C or caspase 3 expression. Here we observed cell death mainly by
late apoptosis vs necrosis because, with the method we used for
cell death detection, we can not distinguish between late apoptosis
vs necrosis. Despite, we have observed a decrease inDwm in agree-
ment with apoptosis. The necrotic contribution may be responsible
for a discrete expression of the tested apoptotic molecules. How-
ever, other apoptotic pathways and proteins may be involved
namely membrane or extrinsic apoptotic pathways (TNF receptors
family as TRAIL receptors) or the Bcl2 family members. We also can
not exclude the possible participation of autophagy cell death
process.
These observations could be related with Yoo et al. [8] showing
that docetaxel sensitizes PC3 apoptosis induced by TRAIL but does
not induce significant changes in the intracellular levels of BCL-2.
Variation in caspase 3 expression is only statistically significant
when comparing to control. On account of that we obtained a sig-
nificant increase of caspase 3 expression in cells treated with so-
dium selenite alone and in combination therapy. The decrease of
caspase 3 expression in the cells treated with the combined ther-
apy, comparing to sodium selenite alone, is not statistically
significant.
On the other hand cell death may be related with oxidative
stress induction. In fact docetaxel has been recently associated to
an increase of ROS in the prostate cancer DU-145 cells [27]. Sur-
prisingly, we found ROS depletion after 24 h treatment (Fig. 4).
Moreover, it could be a result of peroxides conversion into hydro-
xyl radicals. However, data not shown indicate that sodium sele-
nite and docetaxel alone, or in combination, did not interfere on
PC3 peroxides production after 6 h treatment. Therefore, we admit
that sodium selenite could inhibit the antioxidant system leading
to oxidative lesion by reactive hydroxyl radicals and consequent
cell death.
Xiang et al. [15] and Li et al. [14] show that sodium selenite in-
duces apoptosis by generation of superoxide radicals in the LNCaP.
Sodium selenite alters subcellular distribution of manganese
superoxide dismutase (MnSOD), another important antioxidant
defense, inducing its depletion in mitochondria and increase in
cytosol [17]. MnSOD converts superoxide radical into hydrogen,
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inefficient dismutation of superoxide anion into hydrogen perox-
ide, contributing to the observed peroxides reduction. Moreover
it could explain the increased levels of superoxide anion described
by Li et al. [14]. MnSOD overexpression has also been associated to
apoptosis resistance induced by sodium selenite [15].
Reduced glutathione (GSH), counteract oxidative stress by di-
rectly quenching reactive oxygen species and has been associated
to resistance to apoptosis and radiation in prostate cancer cells
[28]. Besides sodium selenite supplies selenium for synthesis of se-
leno-proteins such as the antioxidant defenses glutathione perox-
idase (Gl-Px) and thioredoxin reductase, higher concentrations are
related with increased oxidative stress by decreasing reduced glu-
tathione/oxidized glutathione (GSH/GSSG) ratio and also by alter-
ing MnSOD subcellular distribution. These observations are
related with an increase of ROS levels and cell sensitization to
apoptosis [13–15,29].
Moreover the increase in Bax/Bcl2 ratio, cytochrome C expres-
sion, decrease in mitochondria membrane potential, as well as
the increase in ROS production and the depletion in MnSOD and
GSH/GSSG ratio, as demonstrated by others [13,15,17], reinforce
the contribution of mitochondria on sodium selenite induced
apoptosis. Other intracellular apoptotic pathways must be also
activated by docetaxel and sodium selenite combination, support-
ing that a multitude of cell targets may constitute a new strategy to
overcome drug resistance and may contribute to reduce systemic
toxicity.
Here we can conclude that sodium selenite and docetaxel play a
synergistic antiproliferative effect and significantly induced cell
death, mainly by late apoptosis vs necrosis, which is correlated
with Dwm depletion.
These results may be related with cell cycle arrest (Table 1) and/
or with the production of other ROS species, besides peroxides,
namely, hydroxyl radical or superoxide anion (not measured).
Each drug contribute to cell cycle arrest in agreement with the
observed anti proliferative effect. However, while, docetaxel
induces G2M arrest, sodium selenite, alone or in combination in-
duces S phase arrest. On the other hand, the decrease in peroxides
levels may be related with its conversion into hydroxyl radical.
Moreover it may be a result of a decrease in the dismutation of
superoxide anion.
These findings suggest that docetaxel and sodium selenite com-
bination may be more effective on prostate cancer treatment than
docetaxel alone warranting further evaluation as a new cancer
therapeutic approach.
Moreover, this association, by lowering drug concentration may
be also useful in reducing drug side effects related with systemic
toxicity.
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